Heart Failure Management

Introduction to Heart Failure Treatment

The primary goal of congestive heart failure (CHF) treatment is to improve survival, symptoms, functional capacity, and reduce hospitalization, with a combination of medications including ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and diuretics, as recommended by the American College of Cardiology and the European Heart Society 1, 2, 3
The American College of Cardiology recommends ACE inhibitors as first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF) and hypertension, with specific target doses established in clinical trials to reduce morbidity and mortality 4, 5

Benefits of ACE inhibitors include decreased morbidity and mortality in HFrEF, reduced hospitalizations for heart failure, and improved NYHA functional class and quality of life 4, 6, 3
The European Heart Society and the American College of Cardiology recommend starting ACE inhibitors at a low dose (e.g., Lisinopril 2.5-5mg daily) and titrating upward every 2 weeks to target doses (Lisinopril 20-40 mg daily, Enalapril 10-20 mg twice daily, Ramipril 5 mg twice daily or 10 mg daily) 3, 2
If ACE inhibitors are not tolerated, ARBs are recommended as alternative first-line therapy, with similar efficacy but without causing cough 4, 5, 6
The most common side effects of lisinopril include cough, hypotension, renal insufficiency, hyperkalemia, syncope, and angioedema, with cough being particularly frequent (occurring in up to 20% of patients), as recommended by the American College of Cardiology and supported by evidence from 2, 7, 8

Beta-blockers should be initiated in patients with CHF and low blood pressure only when the patient is hemodynamically stable, with asymptomatic hypotension, starting at the lowest possible dose with gradual titration, and not during acute decompensation, as recommended by the European Society of Cardiology 3
The American College of Cardiology recommends using one of the three proven beta-blockers, Bisoprolol, Carvedilol, or Metoprolol succinate, to reduce mortality, starting at a low dose (e.g., Bisoprolol 1.25mg daily) and doubling every 2 weeks to target doses (Bisoprolol 10 mg daily, Carvedilol 25-50 mg twice daily, Metoprolol CR/XL 200 mg daily) 1, 3, 9
Failure to recognize asymptomatic hypotension, which rarely requires intervention, is a common pitfall in beta-blocker therapy 3
Starting beta-blockers during acute decompensation is not recommended, and patients should be stabilized before initiation 3

Loop diuretics, such as Furosemide and Torsemide, are essential for symptomatic treatment of fluid overload, with the option to add thiazide diuretic for sequential nephron blockade, as suggested by the European Heart Journal and the American College of Cardiology 2
Diuretics should be administered in combination with ACE inhibitors and beta-blockers if tolerated, as recommended by the American College of Cardiology 2
Spironolactone, a mineralocorticoid receptor antagonist, provides additional potassium-sparing effect and is particularly beneficial in moderate to severe heart failure, as suggested by the European Heart Journal, starting at a low dose (e.g., Spironolactone 12.5-25mg once daily) and titrating to maximum doses (e.g., Spironolactone 50mg daily) 2, 9

SGLT2 inhibitors, such as Dapagliflozin or Empagliflozin, should be used at a dose of 10mg daily, regardless of diabetes status, as recommended in 10, 11
The European Heart Journal recommends considering alternative therapies, such as ARNI, for patients who remain symptomatic despite optimal therapy, or for those who cannot tolerate ACE inhibitors, with Angiotensin receptor-neprilysin inhibitors (ARNIs), such as Sacubitril/Valsartan, started at a dose of 24/26mg twice daily and titrated to a target dose of 97/103mg twice daily, as recommended in 10, 2

Regular monitoring of blood pressure, renal function, and electrolytes is recommended 1-2 weeks after initiation or dose changes of ACE inhibitors and diuretics, as advised in 2, 3
Renal function and potassium levels should be monitored, as small increases in creatinine (up to 50% above baseline) are acceptable with ACE inhibitors, as reported in 3
Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in heart failure patients as they can worsen renal function and promote fluid retention, according to 12
Calcium channel blockers like diltiazem and verapamil are contraindicated in HFrEF, as stated in 3
Digoxin can be considered for patients with persistent symptoms despite optimal therapy, particularly useful in patients with atrial fibrillation to control ventricular rate, with a usual daily dose of 0.125-0.25mg, as noted in 12